Legend Biotech
LEGN
141 hedge funds and large institutions have $1.86B invested in Legend Biotech in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 68 increasing their positions, 32 reducing their positions, and 21 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 32
50% more call options, than puts
Call options by funds: $19.3M | Put options by funds: $12.9M
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
1% more funds holding
Funds holding: 139 → 141 (+2)
0.27% more ownership
Funds ownership: 16.43% → 16.7% (+0.27%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
20% less capital invested
Capital invested by funds: $2.34B → $1.86B (-$479M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$40.3M |
| 3 |
BlackRock
New York
|
+$25.3M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$17.6M |
| 5 |
FFM
FengHe Fund Management
Singapore
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$192M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$23.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$19M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$17M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$14.3M |
LEGN Hedge Fund Activity: Q1 2022 in Review
141 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2022, worth a combined $1.86B — down 20% from $2.34B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LEGN positions and 21 closed out — a net gain of 5 holders — while 68 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $63.7M. The largest seller was HHLR Advisors, cutting an estimated $192M.
- 141 institutional investors held Legend Biotech (LEGN) as of Q1 2022, up from 139 in Q4 2021.
- Funds reported $1.86B of Legend Biotech stock for Q1 2022, down 20% quarter-over-quarter.
- 26 funds opened new Legend Biotech positions in Q1 2022 and 21 closed out, a net change of +5 holders.
- The largest Legend Biotech buyer in Q1 2022 was Fidelity Investments, an estimated $63.7M added.
- The largest Legend Biotech seller in Q1 2022 was HHLR Advisors, an estimated $192M sold.
Based on aggregated 13F filings for Q1 2022.